Minerva Neurosciences (NERV) Cash from Operations (2013 - 2026)
Minerva Neurosciences (NERV) posted Cash from Operations of 5400000.0 for Q1 2026, down 20.0% on a QoQ basis from 4500000.0 in Q4 2025, and down 32.61% year-over-year from 8013565.99 in Q1 2025.
Minerva Neurosciences (NERV) Cash from Operations (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Cash from Operations history runs 14 years deep, the most recent figure standing at 5400000.0 for Q1 2026.
- Quarterly Cash from Operations fell 32.61% year-over-year to 5400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14828040.0 (up 15.4% YoY) and the FY2025 annual result came in at 13500000.0, up 30.95% from the prior year.
- Cash from Operations was 5400000.0 for Q1 2026 at Minerva Neurosciences, down from 4500000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 115407.0 in Q1 2023 and bottomed at 9533990.0 in Q3 2022.
- A 5-year average of 4581202.47 and a median of 4500000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 98.01% — and 2024, when it sank 5180.68%.
- Minerva Neurosciences' Cash from Operations stood at 4110076.0 in 2022, then plunged by 45.77% to 5991385.0 in 2023, then rose by 13.76% to 5166784.0 in 2024, then grew by 12.91% to 4500000.0 in 2025, then declined by 20.0% to 5400000.0 in 2026.
- Business Quant data shows NERV's Cash from Operations at 5400000.0 in Q1 2026, 4500000.0 in Q4 2025, and 2885902.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | -4.50 Mn |
| Dec 31, 2025 | -4.50 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -5.99 Mn |
| Dec 31, 2023 | -5.99 Mn |